Rasmussen M, Prado A, Hominal MA, Zaidman CJ, Cursack G, MacKinnon I, Zapata G, Rojas DG, Duran RG, Vilamajo OG, Dutra OP. Global variations in heart failure etiology, management, and outcomes. JAMA. 2023;329(19):1650–61. https://doi.org/10.1001/jama.2023.5942.

Article  Google Scholar 

Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020;9(1):242. https://doi.org/10.3390/cells9010242.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aimo A, Castiglione V, Borrelli C, et al. Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020;27(5):494–510. https://doi.org/10.1177/2047487319870344.

Article  PubMed  Google Scholar 

Kohlhaas M, Nickel AG, Maack C. Mitochondrial energetics and calcium coupling in the heart. J Physiol. 2017;595:3753–63. https://doi.org/10.1113/JP273609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahata SK, Zheng H, Mahata S, Liu X, Patel KP. Effect of heart failure on catecholamine granule morphology and storage in chromaffin cells. J Endocrinol. 2016;230(3):309–23. https://doi.org/10.1530/JOE-16-0146.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riehle C, Bauersachs J. Small animal models of heart failure. Cardiovasc Res. 2019;115(13):1838–49. https://doi.org/10.1093/cvr/cvz161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-1032. https://doi.org/10.1161/CIR.0000000000001063.

Article  PubMed  Google Scholar 

Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(6):671–80. https://doi.org/10.1093/eurheartj/ehaa968.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solomon SD, Jhund PS, Claggett BL, et al. Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF trial. JACC Heart Failure. 2020;8:811–8. https://doi.org/10.1016/j.jchf.2020.04.008.

Article  PubMed  Google Scholar 

Teo YN, Teo YH, Syn NL, et al. Comparing sacubitril/valsartan against sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and network meta-analysis. Clin Drug Investig. 2022;42(1):1–16. https://doi.org/10.1007/s40261-021-01098-3.

Article  CAS  PubMed  Google Scholar 

Karabulut U, Keskin K, Karabulut D, Yiğit E, Yiğit Z. Effect of sacubitril/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fraction. Angiology. 2022;73(4):350–6. https://doi.org/10.1177/00033197211047329.

Article  CAS  PubMed  Google Scholar 

Jiang J, Gao J, Zhang X, et al. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction. Front Cardiovasc Med. 2023;10:1097066. https://doi.org/10.3389/fcvm.2023.1097066.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ko SF, Sung PH, Yang CC, Chiang JY, Yip HK. Combined therapy with dapagliflozin and entresto offers an additional benefit on improving the heart function in rat after ischemia-reperfusion injury. Biomed J. 2023;46(3):100546. https://doi.org/10.1016/j.bj.2022.06.002.

Article  CAS  PubMed  Google Scholar 

Tao W, Yang X, Zhang Q, Bi S, Yao Z. Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later. Front Cardiovasc Med. 2023;10:1181473. https://doi.org/10.3389/fcvm.2023.1181473.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nikolic M, Zivkovic V, Jovic JJ, et al. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart fail rev. 2022;27(3):935–49. https://doi.org/10.1007/s10741-021-10079-9.

Article  CAS  PubMed  Google Scholar 

Nikolic M, Srejovic I, Joksimovic JJ, et al. Sacubitril/valsartan in heart failure and beyond—from molecular mechanisms to clinical relevance. Rev Cardiovasc Med. 2022;23(7):238.

Article  PubMed  PubMed Central  Google Scholar 

Zhou R, Ma P, Xiong A, Xu Y, Wang Y, Xu Q. Protective effects of low-dose rosuvastatin on isoproterenol-induced chronic heart failure in rats by regulation of DDAH-ADMA-NO pathway. Cardiovasc Ther. 2017;35(2):e12241. https://doi.org/10.1111/1755-5922.12241.

Article  CAS  Google Scholar 

Fan C, Tang X, Ye M, et al. Qi-Li-Qiang-Xin alleviates isoproterenol-induced myocardial injury by inhibiting excessive autophagy via activating AKT/mTOR pathway. Front Pharmacol. 2019;10:1329. https://doi.org/10.3389/fphar.2019.01329.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee TI, Chen YC, Lin YK, et al. Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats. Int J Mol Sci. 2019;20(7):1680. https://doi.org/10.3390/ijms20071680.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davidson EP, Coppey LJ, Shevalye H, Obrosov A, Yorek MA. Vascular and neural complications in type 2 diabetic rats: improvement by sacubitril/valsartan greater than valsartan alone. Diabetes. 2018;67(8):1616–26. https://doi.org/10.2337/db18-0062.

Article  CAS  PubMed  Google Scholar 

Zacchigna S, Paldino A, Falcão-Pires I, et al. Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. Cardiovasc Res. 2021;117(1):43–59. https://doi.org/10.1093/cvr/cvaa110.

Article  CAS  PubMed  Google Scholar 

Andjić M, Draginić N, Kočović A, et al. Immortelle essential oil-based ointment improves wound healing in a diabetic rat model. Biomed Pharm. 2022;150:112941. https://doi.org/10.1016/j.biopha.2022.112941.

Article  CAS  Google Scholar 

Joksimovic Jovic J, Sretenovic J, Jovic N, et al. Cardiovascular properties of the androgen-induced PCOS model in rats: the role of oxidative stress. Oxid Med Cell Longev. 2021;2021:8862878. https://doi.org/10.1155/2021/8862878.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bradic J, Jeremic N, Petkovic A, et al. Cardioprotective effects of Galium verum L. extract against myocardial ischemia-reperfusion injury. Arch Physiol Biochem. 2020;126:408–415. https://doi.org/10.1080/13813455.2018.1551904

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.

Article  CAS  PubMed  Google Scholar 

Sretenovic J, Zivkovic V, Srejovic I, et al. Nandrolone decanoate and swimming affects cardiodynamic and morphometric parameters in the isolated rat heart. Life (Basel). 2022;12(8):1242. https://doi.org/10.3390/life12081242.

Article  CAS  PubMed  Google Scholar 

Cruz-López EO, Ye D, Stolk DG, et al. Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects. J Hypertens. 2024;42(5):883–92. https://doi.org/10.1097/HJH.0000000000003633.

Article  CAS  PubMed  Google Scholar 

Ni XY, Feng XJ, Wang ZH, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacol Sin. 2024;45(8):1604–17. https://doi.org/10.1038/s41401-024-01265-0.

Article  CAS  PubMed